Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Chair: GlaxoSmithKline Partnered

McGill University

$330,000.00

Mechanism of action of DNMT1 inhibitors; a pharmacoepigenomic analysis

FY 2012-13

Summary
Our genes that are inherited from our parents are marked by a chemical coating during gestation and are packaged in a highly organized manner in the nucleus of all cells. The chemical coating called "DNA methylation" and the packaging termed "chromatin modification" programs our genes so that they perform their dedicated tasks in the different organs and tissues of our body. We now know that this marking of the genome termed "epigenome" is altered in response to environmental signals. Disruption of the normal pattern of the epigenome results in human disease. One of the hallmarks of cancer is aberrant DNA methylation, which consists of increased methylation of tumor suppressor genes and global hypomethylation. We therefore proposed 16 years ago that DNMT inhibitors are candidate anticancer drugs. The working hypothesis is that inhibition of DNMTs causes DNA demethylation and activation of tumor suppressor genes. It is becoming apparent that changes in DNA methylation play a role not only in cancer but other diseases as well. The proper therapeutic utilization of the vast potential of DNMT inhibitors in cancer as well as other conditions requires that we understand the molecular mechanism of action of DNMT inhibitors. The advances in whole-genome methylation mapping and the progress in our lab in methylome bioinformatics allow us to delineate, at the genomic level, the molecular mechanism of action of DNMT inhibition and unravel their therapeutic potential. In this project, we will define the epigenomic targets that are affected by inhibition of the different DNMT isotypes and their combination in a panel of primary untransformed and cancer cells. Second, we will define the role of active demethylation in the mechanism of action of DNMT inhibitors. Third, we will delineate the mechanisms through which DNMT inhibitors induce the DNA damage response and the therapeutic implications of these mechanisms for developing clinically active DNMT inhibitors.
Program
Chair: GlaxoSmithKline Partnered
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
259684
Name
Szyf Moshe
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
GlaxoSmithKline (Mississauga, Ontario)
Instname2
Genetics
Theme2
Biomedical
Prcname2
CIHR/GSK Partnered Chair Program
Projecttitle
Mechanism of action of DNMT1 inhibitors; a pharmacoepigenomic analysis
Programtype2
Salary Programs
Orgnameinp2
McGill University
Cihramount2
$330,000
Cihrequipment2
$0
Programname2
Chair: GlaxoSmithKline Partnered
Keyworddelim
Cancer; Dna Methylation; Epigenetics
Abstract
Our genes that are inherited from our parents are marked by a chemical coating during gestation and are packaged in a highly organized manner in the nucleus of all cells. The chemical coating called "DNA methylation" and the packaging termed "chromatin modification" programs our genes so that they perform their dedicated tasks in the different organs and tissues of our body. We now know that this marking of the genome termed "epigenome" is altered in response to environmental signals. Disruption of the normal pattern of the epigenome results in human disease. One of the hallmarks of cancer is aberrant DNA methylation, which consists of increased methylation of tumor suppressor genes and global hypomethylation. We therefore proposed 16 years ago that DNMT inhibitors are candidate anticancer drugs. The working hypothesis is that inhibition of DNMTs causes DNA demethylation and activation of tumor suppressor genes. It is becoming apparent that changes in DNA methylation play a role not only in cancer but other diseases as well. The proper therapeutic utilization of the vast potential of DNMT inhibitors in cancer as well as other conditions requires that we understand the molecular mechanism of action of DNMT inhibitors. The advances in whole-genome methylation mapping and the progress in our lab in methylome bioinformatics allow us to delineate, at the genomic level, the molecular mechanism of action of DNMT inhibition and unravel their therapeutic potential. In this project, we will define the epigenomic targets that are affected by inhibition of the different DNMT isotypes and their combination in a panel of primary untransformed and cancer cells. Second, we will define the role of active demethylation in the mechanism of action of DNMT inhibitors. Third, we will delineate the mechanisms through which DNMT inhibitors induce the DNA damage response and the therapeutic implications of these mechanisms for developing clinically active DNMT inhibitors.
Competitiondate
201204
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Szyf, Moshe
Approvedterm
5 ans 0 mois
Cihrcontribution2
Patient Oriented Research~ $330,000~ $0~
McGill University - $330,000 Grant (2012-13) | Canada Spends